1. Show article details.

    Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday

    Benzinga – 3:52 AM ET 08/10/2022

  2. Show article details.

    BRIEF-Avalo Reports Q2 Loss Per Share Of $1.38

    Reuters – 8:21 AM ET 08/04/2022

    Avalo Therapeutics Inc (AVTX): * AVALO REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES. * Avalo Therapeutics Inc (AVTX) - QTRLY LOSS PER SHARE $1.38 Source text for Eikon: Further company coverage:

  3. Show article details.

    Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates

    GlobeNewswire – 7:30 AM ET 08/04/2022

    WAYNE, Pa. and ROCKVILLE, Md., Aug. 04, 2022 -- Avalo Therapeutics, Inc. (AVTX), today announced business updates and financial results for the second quarter of 2022. “We have made significant progress advancing our clinical trials while also securing critical nondilutive capital since our first quarter business update,” said Dr. Garry Neil, President and Chief Executive Officer of Avalo Therapeutics.

  4. Show article details.

    Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

    Benzinga – 6:39 PM ET 08/02/2022

    Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

  5. Show article details.

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    Benzinga – 8:20 AM ET 08/02/2022

      This article was generated by Benzinga's automated content engine and reviewed by an editor.

  6. Show article details.

    Avalo Therapeutics' Shares Climb Following Patient Dosing in Immunodeficiency Disorder Study

    Benzinga – 8:18 AM ET 08/02/2022

    Avalo Therapeutics has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II ER). AVTX-803 is developed and studied for the treatment of leukocyte adhesion deficiency type II. The LADDER trial is a pivotal withdrawal study to assess the efficacy and safety of AVTX-803 in patients with LAD II.

  7. Show article details.

    BRIEF-Avalo Therapeutics Announces First Patient Dosed In The Avtx-803 Pivotal Trial (Ladder) For The Treatment Of Leukocyte Adhesion Deficiency Type Ii (Lad Ii)

    Reuters – 8:03 AM ET 08/02/2022

    Avalo Therapeutics Inc (AVTX): * AVALO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE AVTX-803 PIVOTAL TRIAL FOR THE TREATMENT OF LEUKOCYTE ADHESION DEFICIENCY TYPE II Source text for Eikon: Further company coverage:

  8. Show article details.

    Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

    GlobeNewswire – 7:30 AM ET 08/02/2022

    Avalo Therapeutics, Inc. (AVTX), announced the first patient has been dosed in the pivotal LADDER trial (A Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy and Safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II ER). “We are excited to announce the first patient was dosed in the LADDER pivotal trial.

  9. Show article details.

    Avalo Therapeutics, Apollo Therapeutics Ink Pact For Anti-IL-18 Antibody

    Benzinga – 11:09 AM ET 08/01/2022

    Avalo Therapeutics, Apollo Therapeutics Ink Pact For Anti-IL-18 Antibody

  10. Show article details.

    Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics

    GlobeNewswire – 7:00 AM ET 08/01/2022

    ROCKVILLE, Md. and CAMBRIDGE, United Kingdom, Aug. 01, 2022 -- Avalo Therapeutics, Inc. (AVTX) and Apollo Therapeutics Group Limited have entered into a worldwide, exclusive license agreement granting rights to Apollo to research, develop, manufacture and commercialize AVTX-007, Avalo’s anti-IL-18 monoclonal antibody product. “This transaction is critically important to Avalo.

  11. Show article details.

    Why This Healthcare Stock Dipped Over 75%; Here Are 73 Biggest Movers From Yesterday

    Benzinga – 4:22 AM ET 07/28/2022

    Why This Healthcare Stock Dipped Over 75%; Here Are 73 Biggest Movers From Yesterday

  12. Show article details.

    BRIEF-Avalo Therapeutics Received Written Notification From Nasdaq Confirming That Co Had Regained Compliance

    Reuters – 4:46 PM ET 07/22/2022

    Avalo Therapeutics Inc (AVTX): * Avalo Therapeutics Inc (AVTX) - ON JULY 22, 2022, CO RECEIVED WRITTEN NOTIFICATION FROM NASDAQ CONFIRMING THAT CO HAD REGAINED COMPLIANCE WITH BID PRICE RULE Further company coverage:

  13. Show article details.

    5 Short Squeeze Candidates To Watch This Week: Singing Machine And Revlon Top The List, Chicken Soup For Soul Rejoins

    Benzinga – 10:11 AM ET 07/18/2022

    Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling. A squeeze can occur when short sellers are forced into buying to cover their position, which can cause shares to move up higher on many occasions.

  14. Show article details.

    This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday

    Benzinga – 4:15 AM ET 07/08/2022

  15. Show article details.

    Nasdaq Surges 250 Points; Crude Oil Rises Sharply

    Benzinga – 3:01 PM ET 07/07/2022

    U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping 250 points following the release of data on initial jobless claims. The Dow traded up 1.04% to 31,359.65 while the NASDAQ rose 2.24% to 11,616.84. The S&P also rose, gaining, 1.47% to 3,901.54.

  16. Show article details.

    Dow Jumps More Than 200 Points; Samsung Sees This Much Surge In Quarterly Revenue

    Benzinga – 12:11 PM ET 07/07/2022

    U.S. stocks traded higher midway through trading, with the Dow Jones jumping more than 200 points following the release of data on initial jobless claims. The Dow traded up 0.77% to 31,275.90 while the NASDAQ rose 1.71% to 11,556.29. The S&P also rose, gaining, 1.13% to 3,888.56.

  17. Show article details.

    This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day Session

    Benzinga – 12:02 PM ET 07/07/2022

    This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day Session

  18. Show article details.

    The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill

    Benzinga – 10:03 AM ET 07/07/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours: Merck & Co Inc. is in advanced talks to acquire Seagen Inc.. A purchase agreement is expected in the next few weeks, according to the Wall Street Journal citing people familiar with the matter. The potential deal could be worth more than $40 billion, or above $200 a share.

  19. Show article details.

    BRIEF-Avalo Therapeutics Announces One-For-Twelve Reverse Stock Split

    Reuters – 4:20 PM ET 07/06/2022

    Avalo Therapeutics Inc (AVTX): * AVALO THERAPEUTICS ANNOUNCES ONE-FOR-TWELVE REVERSE STOCK SPLIT. * Avalo Therapeutics Inc (AVTX) - ANNOUNCED A ONE-FOR-TWELVE REVERSE STOCK SPLIT OF COMPANY'S COMMON STOCK, PAR VALUE $0.001 Source text for Eikon: Further company coverage:

  20. Show article details.

    Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split

    GlobeNewswire – 4:05 PM ET 07/06/2022

    Avalo Therapeutics, Inc. (AVTX) today announced a one-for-twelve reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time tomorrow, July 7, 2022. The Company is implementing the reverse stock split as planned to increase the per share price of its common stock to regain compliance with the listing requirements of the Nasdaq Capital Market.

Page:

Today's and Upcoming Events

  • Nov
    07

    AVTX to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    04

    AVTX announced Q2 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.